ProShare Advisors’s Avalo Therapeutics AVTX Stock Holding History

ProShare Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	-$8K	–	1820
2022 Q1	$8K	Sell	4 -1	-20%	-$2.51K	﹤0.01%	2195
2021 Q4	$22K	Buy	+5	New	+$30K	﹤0.01%	2329
2021 Q3	–	Sell	-5	Closed	-$45K	–	2026
2021 Q2	$45K	Buy	5 +1	+25%	+$8.38K	﹤0.01%	2363
2021 Q1	$35K	Buy	+4	New	+$37.8K	﹤0.01%	2246

Other funds holding AVTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's AVTX Position: Q2 2022 in Review

ProShare Advisors sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 4 shares — an estimated $8K sold.

ProShare Advisors first reported a position in AVTX in Q1 2021 and held it in 4 quarters. The position peaked at $45K in Q2 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

ProShare Advisors reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 4 Avalo Therapeutics shares in Q2 2022, an estimated $8K.
ProShare Advisors first reported a position in Avalo Therapeutics in Q1 2021 and held it in 4 quarters.
ProShare Advisors's Avalo Therapeutics position peaked at $45K in Q2 2021.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.